Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes

References

• Kosulin K, Pichler H, Lawitschka A, et al. Diagnostic parameters of adenoviremia in pediatric stem cell transplant recipients. Front Microbiol. 2019;10:414.
   PubMed Web of Science ®Google Scholar
• González‐Vicent M, Verna M, Pochon C, et al. Current practices in the management of adenovirus infection in allogeneic hematopoietic stem cell transplant recipients in Europe: the advance study. Eur J Haematol. 2019;102(3):210–217.
   PubMed Web of Science ®Google Scholar
• Ali S, Krueger J, Richardson SE, et al. The yield of monitoring adenovirus in pediatric hematopoietic stem cell transplant patients. Pediatr Hematol Oncol. 2019;36(3):161–172.
   PubMed Web of Science ®Google Scholar
• Hiwarkar P, Kosulin K, Cesaro S, et al. Management of adenovirus infection in patients after haematopoietic stem cell transplantation: state-of-the-art and real-life current approach: a position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation. Rev Med Virol. 2018;28(3):e1980.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555–563.
   PubMed Web of Science ®Google Scholar
• Bruno B, Gooley T, Hackman RC, et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341–352.
   PubMed Web of Science ®Google Scholar
• Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone marrow transplantation. N Engl J Med. 1985;312(9):529–533.
   PubMed Web of Science ®Google Scholar
• Hsu JM, Artz A, Mayer SA, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(2):359–365.
   PubMed Web of Science ®Google Scholar
• Brown M, Abasov R, Salerno D, et al. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020;61(12):3024–3026.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15(5):610–617.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Champlin RE, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019;3(12):1858–1867.
   PubMed Web of Science ®Google Scholar
• Soriano G, Perales MA. Adenovirus viremia and infection after reduced-intensity allogeneic hematopoietic stem cell transplant: should we institute a routine screening program? Clin Infect Dis. 2012;55(10):1371–1372.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-Seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial. Biol Blood Marrow Transplant. 2016;22(3):S23.
   PubMed Web of Science ®Google Scholar
• Gomez-Arteaga A, Orfali N, Guarneri D, et al. Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplant. 2020;55(12):2298–2307.
   PubMed Web of Science ®Google Scholar
• Kline J, Pollyea D, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37(3):307–310.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27(5):770–781.
   PubMed Web of Science ®Google Scholar
• Rennert H, Ramrattan G, Chen Z, et al. Evaluation of a human adenovirus viral load assay using the Altona RealStar® PCR test. Diagn Microbiol Infect Dis. 2018;90(4):257–263.
   PubMed Web of Science ®Google Scholar
• Ganzenmueller T, Buchholz S, Harste G, et al. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. J Clin Virol. 2011;52(1):55–59.
   PubMed Web of Science ®Google Scholar
• Gustafson I, Lindblom A, Yun Z, et al. Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients. J Clin Virol. 2008;43(1):79–85.
   PubMed Web of Science ®Google Scholar
• Deambrosis D, Davies E, Turner A, et al. Burden of adenoviraemia predicts survival in paediatric recipients of allogeneic haematopoietic stem cell transplant. J Clin Virol. 2020;127:104373.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100(5):1619–1627.
   PubMed Web of Science ®Google Scholar
• Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;10(3):186–194.
   PubMed Web of Science ®Google Scholar
• Sive JI, Thomson KJ, Morris EC, et al. Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clin Infect Dis. 2012;55(10):1362–1370.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Huang Y-T, Kim SJ, et al. Adenovirus viremia in adult CD34(+) selected hematopoietic cell transplant recipients: low incidence and high clinical impact. Biol Blood Marrow Transplant. 2016;22(1):174–178.
   PubMed Web of Science ®Google Scholar
• Huang YT, Kim SJ, Lee YJ, et al. Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34(+) selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1759–1766.
   PubMed Web of Science ®Google Scholar
• Sánchez-Céspedes J, Marrugal-Lorenzo JA, Martín-Gandul C, et al. T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients. Haematologica. 2021;106(1):275–278.
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010;116(25):5476–5485.
   PubMed Web of Science ®Google Scholar
• Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441–462.
   PubMed Web of Science ®Google Scholar
• Kosulin K, Berkowitsch B, Matthes S, et al. Intestinal adenovirus shedding before allogeneic stem cell transplantation is a risk factor for invasive infection post-transplant. EBioMedicine. 2018;28:114–119.
   PubMed Web of Science ®Google Scholar